Bausch Health ehemals VALEANT PHARMA Allergan-Übernahme beflügelt
eröffnet am 30.04.14 17:10:46 von
neuester Beitrag 10.04.24 21:16:45 von
neuester Beitrag 10.04.24 21:16:45 von
Beiträge: 4.274
ID: 1.193.944
ID: 1.193.944
Aufrufe heute: 4
Gesamt: 389.917
Gesamt: 389.917
Aktive User: 0
ISIN: CA0717341071 · WKN: A2JQ1X · Symbol: BHC
8,0900
USD
-7,54 %
-0,6600 USD
Letzter Kurs 02:04:00 NYSE
Neuigkeiten
02.05.24 · Accesswire |
25.04.24 · wO Chartvergleich |
11.04.24 · Accesswire |
11.04.24 · Accesswire |
Werte aus der Branche Pharmaindustrie
Wertpapier | Kurs | Perf. % |
---|---|---|
1,2000 | +471,16 | |
13,110 | +38,44 | |
1,8250 | +35,19 | |
1,2100 | +21,00 | |
27,50 | +19,57 |
Wertpapier | Kurs | Perf. % |
---|---|---|
4,6300 | -11,81 | |
40,23 | -12,54 | |
4,5001 | -13,46 | |
0,9378 | -18,55 | |
36,70 | -22,87 |
Beitrag zu dieser Diskussion schreiben
Tja...
Hätte ich mal lieber... 😜
Hätte ich mal lieber... 😜
Holy Shit!!!
Ich bin jetzt nach einer gefühlten Ewigkeit tatsächlich fast wieder im Plus... 😆
Eigentlich hatte ich immer das Ziel, wenn ich an diesem Punkt angelangt bin, zu verkaufen..
Aber bei dem Lauf, den die Aktie gerade an den Tag legt... (auch wenn ich ihn nicht wirklich verstehe...)
Ich bin jetzt nach einer gefühlten Ewigkeit tatsächlich fast wieder im Plus... 😆
Eigentlich hatte ich immer das Ziel, wenn ich an diesem Punkt angelangt bin, zu verkaufen..
Aber bei dem Lauf, den die Aktie gerade an den Tag legt... (auch wenn ich ihn nicht wirklich verstehe...)
Q1: revenue miss:
die hohen Schulden von ~$20Mrd sind QoQ geblieben,
Ansonsten:
2023 Financial Outlook
The Company confirmed its full year guidance for Bausch Health (excl. B+L) and is providing full year consolidated guidance as follows:
• Full year revenue range of $8.35 - $8.55 billion
• Full year Adjusted EBITDA (non-GAAP)1 range of $3.00 - $3.15 billion
https://ir.bauschhealth.com/news-releases/2023/05-04-2023
die hohen Schulden von ~$20Mrd sind QoQ geblieben,
Ansonsten:
2023 Financial Outlook
The Company confirmed its full year guidance for Bausch Health (excl. B+L) and is providing full year consolidated guidance as follows:
• Full year revenue range of $8.35 - $8.55 billion
• Full year Adjusted EBITDA (non-GAAP)1 range of $3.00 - $3.15 billion
https://ir.bauschhealth.com/news-releases/2023/05-04-2023
Bausch + Lomb names ex-CEO Brent Saunders as CEO, replacing Joseph Papa
https://www.marketwatch.com/story/bausch-lomb-names-ex-ceo-b…
https://www.marketwatch.com/story/bausch-lomb-names-ex-ceo-b…
Antwort auf Beitrag Nr.: 72.080.603 von faultcode am 28.07.22 22:03:20Investment bank Houlihan Lokey wurde bereits engagiert. Damit rückt das Ende hier Richtung Insolvenz (mMn) näher:
22.8.
Bausch Health Hires Advisers Amid Patent Loss, Spinoff Controversy
The company’s debt has been trading in distressed territory since February
https://www.wsj.com/articles/bausch-health-hires-advisers-am…
22.8.
Bausch Health Hires Advisers Amid Patent Loss, Spinoff Controversy
The company’s debt has been trading in distressed territory since February
https://www.wsj.com/articles/bausch-health-hires-advisers-am…
Aha.... 🤔
Bausch Health plummets 50% following judge's Xifaxan patent order
https://seekingalpha.com/news/3862453-bausch-health-plummets…
Bausch Health plummets 50% following judge's Xifaxan patent order
https://seekingalpha.com/news/3862453-bausch-health-plummets…
Wow... das Ding zerreisst es ja gerade komplett??!
4.0900 -4.5900 (-52.8802%)
As of 10:27AM EDT. Market open.
4.0900 -4.5900 (-52.8802%)
As of 10:27AM EDT. Market open.
17.6.
Bausch Health Suspends Plan for IPO of Solta Skin-Care Unit
https://finance.yahoo.com/news/bausch-health-suspends-plan-i…
...
With its own stock battered this year amid volatility and inflation fears, Bausch Health said in a statement Thursday that it decided to suspend its Solta plans “in light of challenging market conditions and other factors.” The company said the interests of its stakeholders are best served in the near-term by focusing on driving Solta’s revenue, profits and cash flow.
“For now, Solta will remain as part of Bausch Health and continue to contribute to the deleveraging of the company’s balance sheet,” according to the statement. “The company will revisit alternative paths for Solta in the future.”
...
Bausch Health Suspends Plan for IPO of Solta Skin-Care Unit
https://finance.yahoo.com/news/bausch-health-suspends-plan-i…
...
With its own stock battered this year amid volatility and inflation fears, Bausch Health said in a statement Thursday that it decided to suspend its Solta plans “in light of challenging market conditions and other factors.” The company said the interests of its stakeholders are best served in the near-term by focusing on driving Solta’s revenue, profits and cash flow.
“For now, Solta will remain as part of Bausch Health and continue to contribute to the deleveraging of the company’s balance sheet,” according to the statement. “The company will revisit alternative paths for Solta in the future.”
...
Antwort auf Beitrag Nr.: 71.511.206 von faultcode am 06.05.22 14:33:25Bausch + Lomb zieht nun doch an:
02.05.24 · Accesswire · Bausch Health Companies |
25.04.24 · wO Chartvergleich · BAVARIA Industries Group Akt |
11.04.24 · Accesswire · Bausch Health Companies |
11.04.24 · Accesswire · Bausch Health Companies |
03.04.24 · Accesswire · Bausch Health Companies |
02.04.24 · Accesswire · Bausch Health Companies |
06.03.24 · Accesswire · Bausch Health Companies |
05.03.24 · Accesswire · Bausch Health Companies |
04.03.24 · wO Chartvergleich · Myriad Genetics |
01.03.24 · Accesswire · Bausch Health Companies |